Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Feb 4, 2026-

Hologic’s Aptima assay secures FDA approval for HPV primary screening

Hologic has received FDA approval for its Aptima HPV assay for use in clinician-collected primary screening.The post Hologic’s Aptima assay secures FDA approval for HPV primary screening appeared first on Medical Device Network.

FDA Expands Approval of Aptima HPV Assay for Cervical Cancer Primary Screening | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA clears mRNA-based HPV test for primary screening, helping clinicians spot cancer-driving infections, cut overtreatment, and personalize care.

Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio - Life Sciences British Columbia

Hologic, Inc. announced that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening.

FDA approves Aptima HPV assay for clinician-collected primary cervical cancer screening | Contemporary OB/GYN